Yuan Ji to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Yuan Ji has written about Clinical Trials, Phase I as Topic.
Connection Strength
3.542
-
The i3+3 design for phase I clinical trials. J Biopharm Stat. 2020 03; 30(2):294-304.
Score: 0.653
-
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. Contemp Clin Trials. 2017 07; 58:23-33.
Score: 0.560
-
Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials. Clin Cancer Res. 2017 Jan 01; 23(1):13-20.
Score: 0.540
-
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol. 2013 May 10; 31(14):1785-91.
Score: 0.423
-
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat. 2012; 22(6):1206-19.
Score: 0.388
-
Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials. 2007; 4(3):235-44.
Score: 0.274
-
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics. 2006 Sep; 62(3):777-84.
Score: 0.268
-
R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. J Biopharm Stat. 2019; 29(3):411-424.
Score: 0.159
-
A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics. 2016 Apr; 17(2):304-19.
Score: 0.127
-
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Stat Med. 2008 Oct 30; 27(24):4895-913.
Score: 0.078
-
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics. 2008 Jul; 9(3):442-57.
Score: 0.073